PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 79 filers reported holding PRELUDE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,298 | -32.3% | 1,066,858 | -1.4% | 0.00% | -100.0% |
| Q2 2023 | $4,871 | +200.3% | 1,082,248 | +280.6% | 0.00% | – |
| Q1 2023 | $1,622 | -10.7% | 284,362 | -5.4% | 0.00% | – |
| Q4 2022 | $1,816 | -99.9% | 300,677 | -4.0% | 0.00% | – |
| Q3 2022 | $2,071,000 | +29.1% | 313,165 | +1.9% | 0.00% | – |
| Q2 2022 | $1,604,000 | -28.0% | 307,353 | -4.8% | 0.00% | – |
| Q1 2022 | $2,229,000 | -41.2% | 322,988 | +6.1% | 0.00% | – |
| Q4 2021 | $3,789,000 | -69.3% | 304,332 | -23.0% | 0.00% | -100.0% |
| Q3 2021 | $12,352,000 | +7.6% | 395,276 | -1.4% | 0.00% | 0.0% |
| Q2 2021 | $11,475,000 | -37.4% | 400,802 | -5.2% | 0.00% | -50.0% |
| Q1 2021 | $18,328,000 | -33.9% | 422,991 | +9.1% | 0.00% | -33.3% |
| Q4 2020 | $27,739,000 | +130.2% | 387,680 | -3.1% | 0.00% | +200.0% |
| Q3 2020 | $12,052,000 | – | 400,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $124,994,000 | 1.61% |
| Baker Brothers Advisors | 10,123,824 | $126,042,000 | 0.61% |
| Pinz Capital Management, LP | 43,800 | $545,000 | 0.21% |
| HHLR ADVISORS, LTD. | 583,333 | $7,262,000 | 0.11% |
| Rock Springs Capital Management LP | 368,959 | $4,594,000 | 0.11% |
| Nan Fung Group Holdings Ltd | 20,350 | $253,000 | 0.08% |
| Virtus ETF Advisers LLC | 13,815 | $172,000 | 0.06% |
| PDT Partners, LLC | 35,907 | $447,000 | 0.03% |
| Jump Financial, LLC | 36,900 | $459,000 | 0.03% |
| Parkwood LLC | 12,667 | $158,000 | 0.03% |